Disease · MONDO_0007739
Targets99
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 99
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | 5 | D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 4 | Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent | Approval | https://conductscience.org/library/genes/6530 | Drugs and targets |
| DRD3 | D(3) dopamine receptor | 3 | D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D3 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 3 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| SLC18A2 | Synaptic vesicular amine transporter | 3 | Synaptic vesicular amine transporter inhibitor | Approval | https://conductscience.org/library/genes/6571 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 2 | D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist | Phase 3 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| FDPS | Farnesyl pyrophosphate synthase | 2 | Farnesyl diphosphate synthase inhibitor | Phase 1 | https://conductscience.org/library/genes/2224 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2905 | Drugs and targets |
| GRIN2D | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2906 | Drugs and targets |
| GRIN3A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/116443 | Drugs and targets |
| GRIN3B | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/116444 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 2 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| PDE10A | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | 2 | Phosphodiesterase 10A inhibitor | Phase 2 | https://conductscience.org/library/genes/10846 | Drugs and targets |
| SLC6A3 | Sodium-dependent dopamine transporter | 2 | Dopamine transporter inhibitor; Dopamine transporter releasing agent | Approval | https://conductscience.org/library/genes/6531 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 2 | Serotonin transporter inhibitor | Phase 2 | https://conductscience.org/library/genes/6532 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 1 | https://conductscience.org/library/genes/25 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007739/targets